公开(公告)号：US20180086813A1

公开(公告)日：2018-03-29

申请号：US15680423

申请日：2017-08-18

Applicant: Wisconsin Alumni Research Foundation

Inventor： Alan C. Rapraeger ,  DeannaLee M. Beauvais ,  Oisun Jung

IPC: C07K14/705 ,  A61K38/17 ,  A61K45/06

CPC classification number: C07K14/70596 ,  A61K38/00 ,  A61K38/177 ,  A61K45/06 ,  C07K14/47 ,  C07K14/4725 ,  C07K14/705 ,  C07K2319/74

Abstract: A fusion peptides with sequences derived from the extracellular domain of syndecan-1 that inhibits VLA-4 and IGF-1R signaling are disclosed. The fusion peptides include an IGF-1R-binding segment having the amino acid sequence LPAGEGPKEGEAVVLPEVEPGLTAREQ (SEQ ID NO:1) and a VLA-4-binding segment having the amino acid sequence sequence DFTFETSGENTA (SEQ ID NO:2).

公开(公告)号：US20180002397A1

公开(公告)日：2018-01-04

申请号：US15616869

申请日：2017-06-07

Applicant: Intrexon Corporation

Inventor： Rutul Shah ,  Tim Chan ,  Peter Emtage ,  Ramya Yarlagadda

IPC: C07K14/705 ,  A61K39/00 ,  C12N5/0783 ,  C07K14/71

CPC classification number: C07K14/70503 ,  A61K39/0011 ,  A61K2039/505 ,  A61K2039/5158 ,  A61K2039/57 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/70596 ,  C07K14/71 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0636 ,  C12N2510/00

Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.

公开(公告)号：US20170368169A1

公开(公告)日：2017-12-28

申请号：US15465564

申请日：2017-03-21

Applicant: ELSTAR THERAPEUTICS, INC.

Inventor： Andreas Loew ,  Brian Edward Vash

IPC: A61K39/395 ,  A61K38/17 ,  A61K39/00

CPC classification number: A61K39/3955 ,  A61K38/1764 ,  A61K38/177 ,  A61K39/39558 ,  A61K2039/507 ,  A61K2039/515 ,  C07K14/4748 ,  C07K14/55 ,  C07K14/70596 ,  C07K14/71 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/75

Abstract: Multispecific molecules that include i) a tumor-targeting moiety; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule; and/or (iv) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

公开(公告)号：US20170368098A1

公开(公告)日：2017-12-28

申请号：US15535972

申请日：2015-12-14

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  SEATTLE CHILDREN'S HOSPITAL DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE

Inventor： Yvonne Y. CHEN ,  Eugenia ZAH ,  Michael C. JENSEN

IPC: A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  C07K16/46 ,  C07K14/705 ,  A61K39/00 ,  A61K38/00

CPC classification number: A61K35/17 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70596 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/46 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/40 ,  C12N5/0636 ,  C12N2510/00

Abstract: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

公开(公告)号：US09840693B2

公开(公告)日：2017-12-12

申请号：US15411125

申请日：2017-01-20

Applicant: Emory University ,  Georgia Tech Research Corporation

Inventor： Michael E. Davis ,  Archana V. Boopathy

IPC: C07K16/00 ,  A61K38/00 ,  C12N5/077 ,  C12N5/00

CPC classification number: C12N5/0657 ,  A61K35/34 ,  C07K14/00 ,  C07K14/70596 ,  C07K2319/70 ,  C07K2319/75 ,  C12N5/0068 ,  C12N2501/42 ,  C12N2533/50

Abstract: This disclosure relates to self-assembling peptides that form hydrogels comprising peptide sequences for the activation of signaling pathways. In certain embodiments, the disclosure relates to compositions comprising a recombinant polypeptide comprising a cell signaling sequence, e.g., JAG-1 sequence, fused to a hydrogel polypeptide sequence. In certain embodiments, the disclosure relates to methods of cell culture on three dimensional scaffolds/hydrogels composed of self-assembling peptides disclosed herein.

公开(公告)号：US09828435B2

公开(公告)日：2017-11-28

申请号：US14892099

申请日：2014-06-20

Applicant: Vaccinex, Inc.

Inventor： Elizabeth E. Evans ,  Ernest S. Smith ,  Maurice Zauderer

IPC: A61K39/395 ,  A61K38/20 ,  A61P35/00 ,  C07K16/28 ,  A61K31/675 ,  C07K16/40 ,  C07K16/32 ,  A61K35/15 ,  C07K16/30 ,  C12N5/0783 ,  C07K14/47 ,  C07K16/18 ,  C07K14/705 ,  A61K39/00

CPC classification number: C07K16/2896 ,  A61K31/675 ,  A61K35/15 ,  A61K38/2013 ,  A61K39/3955 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/572 ,  C07K14/4705 ,  C07K14/70596 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/73 ,  C07K2317/76 ,  C12N5/0638 ,  C12N2501/2302 ,  C12N2501/998 ,  A61K2300/00

Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.

公开(公告)号：US20170258836A1

公开(公告)日：2017-09-14

申请号：US15521741

申请日：2015-10-30

Applicant: The Trustees of the University of Pennsylvania

Inventor： Yangbing Zhao ,  Xiaojun Liu ,  Carl H. June

IPC: A61K35/17 ,  C07K14/715 ,  A01N1/02 ,  C07K16/30 ,  C12N5/0783 ,  C07K16/28 ,  C07K14/705

CPC classification number: A61K35/17 ,  A01N1/02 ,  A61K48/00 ,  A61K2035/124 ,  A61K2039/505 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70596 ,  C07K14/7151 ,  C07K16/2809 ,  C07K16/30 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0636 ,  C12N2501/51 ,  C12N2510/00

Abstract: The present invention includes a method for expanding a population of electroporated T cells. The method includes electroporating a population of cells comprising T cells with mRNA encoding a chimeric membrane protein comprising an antigen binding domain to a molecule and an intracellular domain of a co-stimulatory molecule, wherein the cultured T cells expand at least 10 fold. The invention further includes an expanded population of T cells, compositions comprising the cells and methods of treatment.

公开(公告)号：US09744230B2

公开(公告)日：2017-08-29

申请号：US15058224

申请日：2016-03-02

Applicant: IMMUNOMIC THERAPEUTICS, INC.

Inventor： William Hearl ,  Teri Heiland

IPC: A61K39/35 ,  A61K39/36 ,  C07K14/705 ,  C07K14/415 ,  C07K14/47 ,  A61K39/00

CPC classification number: C07K14/415 ,  A61K39/35 ,  A61K39/36 ,  A61K2039/53 ,  A61K2039/55505 ,  A61K2039/57 ,  A61K2039/577 ,  A61K2039/6031 ,  A61K2039/70 ,  C07K14/47 ,  C07K14/70596 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/06 ,  C07K2319/35

Abstract: The present invention provides DNA vaccines for the treatment of allergies. The vaccines comprise the coding sequence for one or more allergenic epitopes, and preferably the full protein sequence, of the allergenic protein from which the epitope(s) is derived, fused inframe with the lumenal domain of the lysosomal associated membrane protein (LAMP) and the targeting sequence of LAMP. The vaccines allow for presentation of properly configured three dimensional epitopes for production of an immune response. The vaccines can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more DNA constructs.

公开(公告)号：US20170233747A1

公开(公告)日：2017-08-17

申请号：US15444527

申请日：2017-02-28

Applicant: BIOCON LIMITED

Inventor： NAGARAJ GOVINDAPPA ,  KEDARNATH SASTRY ,  MARIA MELINA SOARES

IPC: C12N15/62 ,  A61K39/395 ,  A61K48/00 ,  C12N5/00

CPC classification number: C12N15/62 ,  A61K38/00 ,  A61K38/10 ,  A61K38/179 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61K48/005 ,  A61K2039/505 ,  A61K2121/00 ,  C07K7/08 ,  C07K14/00 ,  C07K14/495 ,  C07K14/65 ,  C07K14/70532 ,  C07K14/70596 ,  C07K14/71 ,  C07K16/2818 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/732 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/33 ,  C12N5/0018 ,  C12N2500/22 ,  G01N33/6854

Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.

公开(公告)号：US20170233453A1

公开(公告)日：2017-08-17

申请号：US15437968

申请日：2017-02-21

Applicant: OncoImmune, Inc.

Inventor： Xincheng Zheng ,  Wei Wu ,  Yang Liu ,  Pan Zheng

IPC: C07K14/705

CPC classification number: C07K14/70596 ,  C07K14/435 ,  C07K14/47 ,  C07K19/00 ,  C07K2319/30

Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.